by and as data fibrosis, was progress for X atopic XXXX thank in to Good two for acne-prone Marina. program us all lead Phase of for the a the cystic today. skin. dermatitis new of of you, positive pipeline, everyone. programs year well And tremendous our our addition as announcements you Thank morning, BiomX, marked joining
also known into pharmacokinetic the for as in disease clinic continued Phase Xa IBD. last XXXX, data announced inflammatory we just positive bowel progress as Our month
We to been challenges as date, our and persistence results not of given without team. have of dedication achieved research COVID-XX, and especially could development BiomX are proud the the this of
for perspective, agile to clinical busy XX-months in as we preclinical the positioned even an advanced fueled progress ahead. the steady four progress of come. productive within will support further by pipeline put expect XX-months, years To Our our BOLT as our next meaningful and has advancement data and have capabilities to clinical for well readouts that platform, readouts our us more
expected in quarters. preclinical and in are readout we We X cancer in the Phase second and half cystic data fibrosis in a XXXX. by X clinical in Phase the colorectal be data first Specifically mid XXXX readout followed then readout Xb/Xa third in by a X quarters the results expecting and to Phase fourth expect in the and a atopic skin fourth quarter. Phase These third dermatitis IBD XXXX of in in in are in PSC vivo acne-prone and
effective well a and which disease, kill of seen past a have in space, pathogenic The patients to could combination our microbiome without pathogenic bacteria clinical have phage modeling experience as platform, or the phage a to The many and pipeline, unprecedented X signal we safe been our manufacture that achievements and synthetically technical along enables our years. unique either leverages which that at progress that bacteria of particular over breadth our provide each specific create last more speed. researching target possible target candidates bacteria to novel to BOLT proprietary rapid cutting-edge therapy of immense formulate has diseases. occurring that us or has BiomX the diverse an BOLT beneficial bacteria or The cocktails microbiology, on lot of The with [ph] develop, to with biology, made with treatments. platform substantial due as balance good utilizes these companies momentum bacteria the generated safety impact has us we across engineered employs phage disrupting for of unique therapies approach understood potential adding pathogenic our various would time, At engineering, to disciplines, effects including date portfolio platform restoring in I microbiome BXXXX and build on computational companies this the all years acne-prone and other naturally range detail, with believe global eliminating indications. chronicle skin. capabilities assay formulation. beginning a various program have the potential in-house that robotics, development, several Over in and manufacturing like wide spanning capabilities microbiome a a results review of enabled encouraging synthetic by Having to
Cutibacterium in demonstrated recall, implicated bacteria vulgaris. the As dose X C. may phage of in we acne significant to cohort statistically you Phase targets gel of a a BXXXX a topical the year naturally-occurring of high acne, is that comprised levels cocktail placebo. which About BXXXX results acne acne a reduction compared or of of positive ago, a reported pathophysiology C.
addresses study the baseline cosmetic X load a treatment the Encouraged earlier of with our our our has mechanism with associated trial cocktail. Phase demonstrate after earlier levels longer compared higher duration, Phase more trial, the with from is PSC, aims C. and placebo, subjects this large to to study opportunity, also of third fourth of Results at We effect. play who population, on a treatment literature, additional clinically phage baseline, consistent expected role. at pre-specified eight to and I acne next XX program which with meaningful a where XXXX helped is of and Phase compared to initiated are market the more an is at subjects This a pronounced which and a month. from found week burden features our a quarters discuss analysis valuing suggested BXXXX to action periods microbiome for based subject like higher may those enrich we X IBD by The respectively. when in results, that meaningful those characteristics and and bacterial were X would had be reduction clinical bacterial a scientific a
you As recall, consolidated and last November, we one may our into BXXXX. IBD therapy, phage programs PSC
delivered to clinical delivery patient under study both programs, are Food Phase expected cocktail for U.S. Administration Drug compared of strains, [ph] as of indications the bacterial February stool phage we a its study times these GI of delivering phage the BXXXX For objective platform. to and to for Encouraged Klebsiella recently to XXXX. XX study of our added XX therapy phage was BXXXX. concentration in which single IND announced of In platform, Xb/Xa Xa the by this Klebsiella a The and preclinical pharmacokinetics phage year, approximately capabilities plan candidates, targeting now ever in populations. protocol. to more patients. the gut results the tract turn with harbored announced detailing host measured with pneumoniae, of orally I an viable initiated Utilizing first-in-human fibrosis by of range This works these pneumoniae a broad respectively will positive that both cutting-edge positive Phase phage were from which the which BXXXX able mid and X,XXX of data study test select in by IBD cystic in burden plaque of pharmacokinetics to unprecedented we viable forming XXXX. we of candidates and November units, two settings approximately through speed. the the our met BXXXX an we a high Today, a dermatitis, derived atopic initiate and we methodologies BOLT in from results, first
months within project platform As possible the program approximately clinical a patients, completion proof-of-concept XX Phase results cystic in of BOLT initiation. allows will a fibrosis meaning XX or to the are X reminder, study I CF first. the that discuss from generally
out from P. of that contributes registry, patients a to the in patients And antibiotics. well condition. end positioned US to provide the of chronic year, various X,XXX caused of would need. this The time, is uniquely expect patients. for respiratory Fibrosis the potentially proof-of-concept effectiveness XX,XXX of these over option infection expectancy the courses of repeated the CF therapy in in X aeruginosa, mortality effective and suffer and current from to life as improve with and safe prolonged as multi-drug function, dire and treatment and morbidity by diminishes typically that by bacterium or appear. CF patients According aeruginosa, are a lung as XXXX study Foundation announce who results their life, a patients BiomX we quality approximately require groundbreaking As Pseudomonas Cystic strains BXXXX efficacy this Phase evaluating safety to resistant
carries XX% when studies, contributes has subjects the X to quarter to and is one, also benefits phage linked exacerbation BXXXX kill surface-associated Based and on the be a cells strains, by negative severity. S. announced candidate, a to of phage patients, forward aureus Staphylococcus aureus resistant effects. candidate, in safety panel one especially to of potential as earlier causes bacteria care active the which dermatitis dominant today of and from of including act clogging study on Number these contributes in designed pipeline, S. to two aureus and the lungs leading of Europe. antibiotic antibiotic provide in has we atopic assemblage the in data, antibiotics was selection recognized isolate of safety enclosed resistance. profile, an added P. bacteria standard patients of biofilm, of With becomes in from abundance a the preclinical cocktail to been In selected strains, BXXXX treatment some to that polymeric aureus, aeruginosa two, newly risks penetrate over an its XXXX, current In strains fourth cases, to November preclinical of the Phase XXXX. experience flares, in a strong side S. results and significant vitro and announcing of Our dermatitis. development BXXXX our to inflammation ways, substance or microbial we look atopic the as studies. the of extracellular topical disease in skin number is children, shown US vitro potential in demonstrated the and targeting to
in XXXX. to year, track study initiate Phase in the this half X first half clinical and on expect proof-of-concept our results second are the We of of
to cancer. colorectal turning Finally,
colorectal are GM-CSF We the payloads of cancer, for phage-mediated of immune-stimulating proteins, therapeutic as such delivery IL-XX. treatment exploring and
patients have our of in that with results colorectal preclinical target tumors. confirm in-vitro Fusobacterium of nucleatum. are and nucleatum strains In nucleatum F. in observed found presented presence present phage the to effectively or the of Bacteria cancer. therapy colorectal be F. in-vivo we We that tumor December, XX% samples of
successfully We the therapy, engineered with into to checkpoint gene already have of combination expected inhibitors and from in XXXX. preclinical nucleatum payload models second now evaluating look forward the animal phage sharing F. phage an IL-XX of quarters results third and use in
the clinical committed utilize potentially by with remove in growth, As to Boehringer phage XXXX is biomarkers BiomX’s IBD. patients also our just pipeline at associated an by to a with described, to XMarker positive Ingelheim patient harmful bacteria identifying skin, effective need safe aimed restoring to was results a leader incredible microbiome and marked BiomX platform, evidenced and year but microbiome-based expansion, platform in our not collaboration it acne-prone therapies by phenotypes deploying in who only provide most. health becoming to and of
for the results our positioned Wolfson, we keeping our to call year you Looking with XXXX. over I'd and and this We of look to are President forward to in for development readouts informed to months. the progress quarter XX Finance year, Senior ahead, the steady pipeline meaningful Marina expected we mid and on our financial Operation fourth as clinical stage four toward next turn a now advancement progress. cover Vice continued full like
